-
2022 IPO, Venture Capital and M&A Reports
2.28.2022WilmerHale’s annual IPO, Venture Capital and M&A reports provide insights into market conditions, as well as comprehensive statistics and analysis that are hard to find elsewhere.
-
2022 Venture Capital Report
2.28.2022The 2022 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.
-
2022 M&A Report
2.28.2022The 2022 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
2022 IPO Report
2.28.2022The 2022 IPO Report offers a detailed IPO market review and outlook, including regional breakdowns, plus useful market metrics and articles on topics of interest for pre-IPO companies
-
Recent Venture Financings as Company Counsel: 2022
1.28.2022In 2021, we served as counsel in more than 250 venture financings raising approximately $20 billion, including some of the largest and most prominent deals of the year.
-
WilmerHale Advises GentiBio in $157M Series A Funding
8.11.2021On August 11, 2021, GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, announced it has closed a Series A financing generating immediate proceeds of $157 million.
-
WilmerHale Advises Embark Veterinary in $75M Series B Funding
7.27.2021On July 26, 2021, Embark Veterinary, Inc., the top rated provider of dog DNA tests, announced that it secured $75 million in a Series B funding round led by SoftBank.
-
2021 IPO, Venture Capital and M&A Reports
4.26.2021WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.
-
2021 Venture Capital Report
4.26.2021The 2021 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.
-
2021 M&A Report
4.26.2021The 2021 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
2021 IPO Report
4.26.2021The 2021 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest for pre-IPO companies.
-
WilmerHale Advises Volastra Therapeutics in Extended $44M Seed Financing
4.6.2021On April 6, 2021, Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, announced the extension of its original $12 million seed round to a total of $44 million.
-
Recent Venture Financings as Company Counsel: 2021
3.5.2021In 2020, we served as counsel in more than 200 venture financings raising in excess of $10 billion, including some of the largest and most prominent deals of the year. Since 2010, we have handled approximately 2,700 venture financings with total proceeds in excess of $48 billion.
-
WilmerHale Advises Xilio Therapeutics In $95M Series C Financing
2.25.2021On February 24, 2021, Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, announced the successful closing of a $95 million Series C financing round.
-
WilmerHale Represents Verve Therapeutics in $94M Series B Financing
1.22.2021On January 19, 2021, Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, announced the successful completion of a $94 million Series B financing.
